Publications by authors named "A L Mutka"

Objectives: Evaluating invasion in non-mucinous adenocarcinoma (NMA) of the lung is crucial for accurate pT-staging. This study compares the World Health Organization (WHO) with a recently modified NMA classification.

Materials And Methods: A retrospective case-control study was conducted on small NMA pT1N0M0 cases with a 5-year follow-up.

View Article and Find Full Text PDF

While is the most frequently mutated oncogene in non-small cell lung cancer (NSCLC), -mutant tumors have long been considered difficult to treat and thus, an unmet need still remains. Partly due to the lack of targeted treatments, comprehensive real-world description of NSCLC patients with mutation is still largely missing in Finland. In this study, all adult patients diagnosed with locally advanced and unresectable or metastatic NSCLC from 1 January 2018 to 31 August 2020 at the Hospital District of Helsinki and Uusimaa were first identified in this retrospective registry-based real-world study.

View Article and Find Full Text PDF

Familial cardiomyopathy in pediatric stages is a poorly understood presentation of heart disease in children that is attributed to pathogenic mutations. Through exome sequencing, we report a homozygous variant in tropomodulin 1 (TMOD1; c.565C>T, p.

View Article and Find Full Text PDF

Background: We aimed to quantify ductular reaction (DR) in biliary atresia using a neural network in relation to underlying pathophysiology and prognosis.

Methods: Image-processing neural network model was applied to 259 cytokeratin-7-stained native liver biopsies of patients with biliary atresia and 43 controls. The model quantified total proportional DR (DR%) composed of portal biliary epithelium (BE%) and parenchymal intermediate hepatocytes (PIH%).

View Article and Find Full Text PDF
Article Synopsis
  • Testing for EGFR mutations is crucial for metastatic non-squamous non-small-cell lung cancer, but practical challenges like access to testing and limited tissue samples hinder routine biomarker testing in European labs.
  • A validated online survey conducted among 64 expert labs revealed varying turnaround times and testing practices, with a significant portion only conducting EGFR testing upon clinician request.
  • Despite these issues, testing rates remained stable during the COVID-19 pandemic, but overall there is significant variability in testing methods and quality assurance across different European laboratories.
View Article and Find Full Text PDF